Francesco Bifari

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression.

Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression.

Journal: Pharmacological research

Published: June 05, 2026

Corneal regenerative contribution of endogenous and grafted limbal-corneal cells in a mouse model of simple limbal-corneal epithelial transplantation.

Corneal regenerative contribution of endogenous and grafted limbal-corneal cells in a mouse model of simple limbal-corneal epithelial transplantation.

Journal: Stem cells translational medicine

Published: April 14, 2025

Continuous interstitial glucose monitoring in diabetic and non-diabetic critically ill patients is simple and accurate: comparison with venous, arterial and capillary glucose measurements.

Continuous interstitial glucose monitoring in diabetic and non-diabetic critically ill patients is simple and accurate: comparison with venous, arterial and capillary glucose measurements.

Journal: Acta diabetologica

Published: March 28, 2025

Protocol to develop a preclinical severe contusive-compressive SCI mouse model for translational research.

Protocol to develop a preclinical severe contusive-compressive SCI mouse model for translational research.

Journal: STAR protocols

Published: March 11, 2025

Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE- 2 study.

Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE- 2 study.

Journal: Pharmacological research

Published: January 30, 2025

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.

Journal: Pharmacological research

Published: October 22, 2024

Synergistic effects of glucose tolerance and BMI on cardiovascular events and all-cause mortality in a healthy population: CA.ME.LI.A study 7 years follow-up.

Synergistic effects of glucose tolerance and BMI on cardiovascular events and all-cause mortality in a healthy population: CA.ME.LI.A study 7 years follow-up.

Journal: American journal of physiology. Endocrinology and metabolism

Published: August 28, 2024

Tumor-associated macrophages enhance peripheral nerve tumor infiltration and spinal cord repair.

Tumor-associated macrophages enhance peripheral nerve tumor infiltration and spinal cord repair.

Journal: Immunity

Published: July 31, 2024

AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus.

AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus.

Journal: Acta diabetologica

Published: March 01, 2023

Consistency and Variation in Doublecortin and Ki67 Antigen Detection in the Brain Tissue of Different Mammals, including Humans.

Consistency and Variation in Doublecortin and Ki67 Antigen Detection in the Brain Tissue of Different Mammals, including Humans.

Journal: International journal of molecular sciences

Published: December 16, 2022

Esmethadone-HCl (REL-1017): a promising rapid antidepressant.

Esmethadone-HCl (REL-1017): a promising rapid antidepressant.

Journal: European archives of psychiatry and clinical neuroscience

Published: November 28, 2022

REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants: A Report of 2 Cases.

REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants: A Report of 2 Cases.

Journal: Journal of clinical psychopharmacology

Published: August 09, 2022

Showing 1-12 of 45

Last Updated: 09/26/2026